TY - JOUR
T1 - Extracorporeal Membrane Oxygenation in Patients With COVID-19
AU - Sreenivasan, Jayakumar
AU - Ranka, Sagar
AU - Lahan, Shubham
AU - Abu-Haniyeh, Ahmed
AU - Li, Heyi
AU - Kaul, Risheek
AU - Malik, Aaqib
AU - Aronow, Wilbert S.
AU - Frishman, William H.
AU - Lansman, Steven
N1 - Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Coronavirus disease 2019 (COVID-19) is characterized by a clinical spectrum of diseases ranging from asymptomatic or mild cases to severe pneumonia with acute respiratory distress syndrome (ARDS) requiring mechanical ventilation. Extracorporeal membrane oxygenation (ECMO) has been used as rescue therapy in appropriate patients with COVID-19 complicated by ARDS refractory to mechanical ventilation. In this study, we review the indications, challenges, complications, and clinical outcomes of ECMO utilization in critically ill patients with COVID-19-related ARDS. Most of these patients required venovenous ECMO. Although the risk of mortality and complications is very high among patients with COVID-19 requiring ECMO, it is similar to that of non-COVID-19 patients with ARDS requiring ECMO. ECMO is a resource-intensive therapy, with an inherent risk of complications, which makes its availability limited and its use challenging in the midst of a pandemic. Well-maintained data registries, with timely reporting of outcomes and evidence-based clinical guidelines, are necessary for the careful allocation of resources and for the development of standardized utilization protocols.
AB - Coronavirus disease 2019 (COVID-19) is characterized by a clinical spectrum of diseases ranging from asymptomatic or mild cases to severe pneumonia with acute respiratory distress syndrome (ARDS) requiring mechanical ventilation. Extracorporeal membrane oxygenation (ECMO) has been used as rescue therapy in appropriate patients with COVID-19 complicated by ARDS refractory to mechanical ventilation. In this study, we review the indications, challenges, complications, and clinical outcomes of ECMO utilization in critically ill patients with COVID-19-related ARDS. Most of these patients required venovenous ECMO. Although the risk of mortality and complications is very high among patients with COVID-19 requiring ECMO, it is similar to that of non-COVID-19 patients with ARDS requiring ECMO. ECMO is a resource-intensive therapy, with an inherent risk of complications, which makes its availability limited and its use challenging in the midst of a pandemic. Well-maintained data registries, with timely reporting of outcomes and evidence-based clinical guidelines, are necessary for the careful allocation of resources and for the development of standardized utilization protocols.
KW - COVID-19
KW - SARS-CoV-2
KW - acute respiratory
KW - distress syndrome
KW - extracorporeal membrane oxygenation
UR - http://www.scopus.com/inward/record.url?scp=85128245801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128245801&partnerID=8YFLogxK
U2 - 10.1097/CRD.0000000000000410
DO - 10.1097/CRD.0000000000000410
M3 - Review article
C2 - 34292184
AN - SCOPUS:85128245801
SN - 1061-5377
VL - 30
SP - 129
EP - 133
JO - Cardiology in review
JF - Cardiology in review
IS - 3
ER -